Faran S Polani, Clinical Investigator at NEXT Oncology, shared on LinkedIn:
“PRMT5 inhibition is rapidly transitioning from an elegant synthetic – lethal construct to a clinically actionable therapeutic class.
Our perspective in American Society of Clinical Oncology (ASCO) Daily News examines the emerging data in MTAP – deleted malignancies and, more importantly, the developmental questions ahead, optimal positioning, biologically coherent combinations, and the potential convergence of PRMT5 and RAS – directed therapeutics.
This is precisely where early drug development becomes most interesting: translating mechanistic orthogonality into therapeutic complementarity.
A privilege to work alongside Shiraj Sen and contribute to this evolving space at NEXT Oncology, an Avacare business Texas Oncology.”
Title: Targeting MTAP Deletions: PRMT5 and RAS Inhibitors Show Clinical Promise
Authors: Faran Polani and Shiraj Sen
Other articles featuring Faran S Polani on OncoDaily.